SCHEMBL14045787

SCHEMBL14045787

CC(O)C(NS(=O)(=O)c1ccc2cccnc2c1)C(=O)ON

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.42
SLC1A2 P43004 1/20 0.42
SLC1A1 P43005 1/20 0.42
MMP1 P03956 3/20 0.41
ADAM17 P78536 3/20 0.41
ADAMTS4 O75173 7/20 0.41
ALDH1A1 P00352 2/20 0.39
LOXL2 Q9Y4K0 2/20 0.39
MMP13 P45452 6/20 0.38
MMP9 P14780 2/20 0.37
ADAM10 O14672 1/20 0.37
MMP7 P09237 1/20 0.37
MMP8 P22894 1/20 0.37
MMP14 P50281 1/20 0.37
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MMP12 P39900 2/20 0.36
CYSLTR1 Q9Y271 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14025844 0.85 MMP1 (0.54) MMP1ADAM17MMP13MMP9ADAM10
SCHEMBL4915080 0.85 MMP1 (0.54) MMP1ADAM17MMP13MMP9ADAM10
SCHEMBL14045868 0.83 SLC1A3 (0.60) SLC1A3SLC1A2SLC1A1ADAM17ADAMTS4
SCHEMBL14045735 0.76 SLC1A3 (0.41) SLC1A3SLC1A2SLC1A1MMP1ADAM17
SCHEMBL14045830 0.74 SLC1A3 (0.57) SLC1A3SLC1A2SLC1A1MMP1ADAM17
SCHEMBL14045736 0.73 ADAMTS4 (0.64) SLC1A3SLC1A2SLC1A1MMP1ADAMTS4
SCHEMBL20998631 0.72 ALDH1A1 (0.50) MMP1ALDH1A1LOXL2MMP13MMP9
SCHEMBL11681712 0.72 LOXL2 (0.50) ALDH1A1LOXL2LMNASMN1; SMN2
SCHEMBL4928565 0.70 MMP2 (0.45) ALDH1A1LOXL2MMP13MMP9MMP8
SCHEMBL25517468 0.70 ALDH1A1 (0.50) ALDH1A1LOXL2LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof AOC2, AOC3, AOC1 SLC1A3 217/4885SLC1A2 434/4885SLC1A1 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.